摘要
非小细胞肺癌(NSCLC)的高病死率多源于其转移与复发,如能在疾病早期通过临床检验明确诊断,有望改变NSCLC患者的生存率。近年来,许多学者通过免疫组化、反转录-聚合酶链反应等方法分别从分子生物水平、基因水平来研究与NSCLC关系密切的分子学标志物。其中肺组织特异性X蛋白(LunX)在非小细胞肺癌的检测中有较高的敏感性和特异性。现对LunX与NSCLC的微转移、病理分型、分期、治疗模式及预后等研究进展进行综述。
The high mortality of non-small cell lung cancer（NSCLC） patients owes to its metastasis and recurrence. The survival rate may be changed if it could be diagnosed in the early stage through clear clinical method. Recently, many researchers take up with molecular markers which are considered to be associated with NSCLC through immunohistochemistry and reverse transcriptase-polymerase chain reaction in both molecularbiological and genetic level. LunX is regarded as one of the useful diagnostic markers in NSCLC patients,which owns high sensitivity and specificity. Here is to summarize the relationship between LunX and NSCLC in its micrometastasis, pathlogy, staging, therapy and prognosis and etc,.
出处
《医学综述》
2011年第17期2680-2682,共3页
Medical Recapitulate
基金
内蒙古自治区科学基金(2009MS1119)
